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Abstract
Background: Most studies related to healthcare-associated infection (HAI) were conducted in the developed countries. We
sought to determine healthcare-associated infection rates, microbiological profile, bacterial resistance, length of stay (LOS), and
extra mortality in one ICU of a hospital member of the International Infection Control Consortium (INICC) in Morocco.
Methods: We conducted prospective surveillance from 11/2004 to 4/2008 of HAI and determined monthly rates of central
vascular catheter-associated bloodstream infection (CVC-BSI), catheter-associated urinary tract infection (CAUTI) and
ventilator-associated pneumonia (VAP). CDC-NNIS definitions were applied. device-utilization rates were calculated by dividing
the total number of device-days by the total number of patient-days. Rates of VAP, CVC-BSI, and CAUTI per 1000 Device-days
were calculated by dividing the total number of HAI by the total number of specific Device-days and multiplying the result by
1000.
Results: 1,731 patients hospitalized for 11,297 days acquired 251 HAIs, an overall rate of 14.5%, and 22.22 HAIs per 1,000 ICU-
days. The central venous catheter-related bloodstream infections (CVC-BSI) rate found was 15.7 per 1000 catheter-days; the
ventilator-associated pneumonia (VAP) rate found was 43.2 per 1,000 ventilator-days; and the catheter-associated urinary tract
infections (CAUTI) rate found was 11.7 per 1,000 catheter-days.
Overall 25.5% of all Staphylococcus aureus HAIs were caused by methicillin-resistant strains, 78.3% of Coagulase-negative-
staphylococci were methicillin resistant as well. 75.0% of Klebsiella were resistant to ceftriaxone and 69.5% to ceftazidime. 31.9%
of E. Coli were resistant to ceftriaxone and 21.7% to ceftazidime. 68.4% of Enterobacter sp were resistant to ceftriaxone, 55.6%
to ceftazidime, and 10% to imipenem; 35.6% of Pseudomonas sp were resistant to ceftazidime and 13.5% to imipenem.
LOS of patients was 5.1 days for those without HAI, 9.0 days for those with CVC-BSI, 10.6 days for those with VAP, and 13.7
days for those with CAUTI.
Extra mortality was 56.7% (RR, 3.28; P =< 0.001) for VAP, 75.1% (RR, 4.02; P = 0.0027) for CVC-BSI, and 18.7% (RR, 1.75; P =
0.0218) for CAUTI.
Conclusion: HAI rates, LOS, mortality, and bacterial resistance were high. Even if data may not reflect accurately the clinical
setting of the country, programs including surveillance, infection control, and antibiotic policy are a priority in Morocco.
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Background
The industrialized countries have established standard-
ized criteria for the devise of institutional healthcare-asso-
ciated infection (HAI) surveillance and infection control
(IC) measures [1]. Most studies related to HAI were con-
ducted in the developed countries [2-4] and demon-
strated the efficacy of HAI surveillance [3-5] and its
significant incidence concerning patient morbidity and
mortality [6].
Conversely, in the developing countries, few studies pro-
vide data of device associated infection rates using the
standardized definitions HAI rates per 1000 device
days[7-11]. In Morocco, there is one published study on
prevalence of HAI conducted in a university hospital,
which showed a significantly high HAI rate [12].
This study presents data collected by the INICC that show
HAI in a Moroccan ICU with the aim of benchmarking
them with regional and international standards and assess




A prospective study was performed of all patients consec-
utively admitted to a 12-bed medical ICU of Rabat Uni-
versity Hospital between November 2004 and April 2008.
Rabat University Hospital is the referral venue for habit-
ants in western-north Morocco. The 12-bed medical ICU
admits approximately 550 patients annually with an aver-
age age of 40 years. Surgery patients, coronary patients,
neonates and burn patients are treated in specialized
units.
The hospital has an infection control team (ICT) with a
physician and an infection control practitioner (ICP) with
16 years of experience (Table 1) and a microbiology labo-
ratory to provide in vitro susceptibility testing of clinical
isolates using standardized methods.
The hospital's institutional review board agreed to the
study protocol, and patient confidentiality was protected
by codifying the recorded information making it only
identifiable to the ICT. Informed consent was not
demanded because this observational study did not
require any deviation from routine medical practice.
Surveillance
Rates of central vascular catheter-associated bloodstream
infection (CVC-BSI), catheter-associated urinary tract
infection (CAUTI) and ventilator-associated pneumonia
(VAP) were determined monthly, and CDC-NNIS defini-
tions were applied [13,14].
Crude Excess Mortality
Crude excess mortality is the difference between the crude
overall case-fatality of patients with HAI and the crude
case-fatality of patients without HAI in the ICU during the
same period.
Length of stay (LOS) was collected prospectively when
filling INICC forms daily. Adult patients with HAI were
considered cases, while those without HAI were consid-
ered controls. We calculated extra-LOS subtracting average
LOS of patients with and without HAI.
Training, Forms, Validation, and Data Feedback
The INICC chairman (Victor D Rosenthal) provided train-
ing procedures related to surveillance to the participating
hospital, which daily filled forms including data related to
patient, such as demographics, age, gender, severity of ill-
ness score, and hospital location. These data were gath-
ered at admission to the ICU. After admission, data on
mechanical ventilation (MV), placement of central vascu-
lar catheter (CVC) and urinary catheters (UC), fever,
blood pressure, antibiotic use, and the results of cultures
on patients hospitalized in the ICU were collected. Upon
the end of hospitalization, the ICP registered data regard-
ing patients with HAI that included the date of onset, site
of HAI, infecting microorganisms and their antibiotic sus-
ceptibilities.
The average severity of illness score (ASIS) was recorded
by using the CDC-NNIS criteria [14].
Patients in the ICU had a check-off when the ICP in charge
of reviewing the filled forms was satisfied that the clinical
and microbiologic criteria for the specific type of HAI had
been met. The ICT in Morocco had access to a team at the
central office (CO) in Buenos Aires, which provided
Table 1: Patients characteristics
Surveillance Period 11/04 to 04/08
Experience of the infection control practitioner, y 16
Patients studied, n 1.731
Total ICU days, d 11.297
Men, % 52.4
Mean age, y, ± SD 42.4 ± 19.2
Mean ASIS, ± SD 3.9 ± 0.7
Mean APACHE II, ± SD 11.5 ± 8.2
Device use
Ventilator days, d 3.2
Ventilator use, proportion 0.28
CVC days, d 2.2
CVC use, proportion 0.19
Urinary catheter days, d 6.8
Urinary catheter use, proportion 0.60
ASIS = average severity of illness score; CVC = central venous 
catheter; ICU = intensive care unit.International Archives of Medicine 2009, 2:29 http://www.intarchmed.com/content/2/1/29
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responses checked by the chairman to inquiries within 24
hours.
Filled out forms were sent monthly from each ICT to the
CO, where an HAI adjudication process of each case was
performed by analyzing the recorded signs (Fever, Blood
pressure) and cultures, in order to assure that the CDC
NNIS criteria for HAI were met [13,14]. Lastly, the forms
were further uploaded in the database. The CO team pre-
pared and sent to the ICT monthly reports, showing glo-
bal rates per 100 patients and per 1000 bed-days, HAI per
1000 device-days, microbiological profile, extra mortality
by type of HAI, extra-LOS, hand hygiene compliance
(HHC), and CVC and UC care compliance.
The HHC was observed and monitored before patient
contact by a randomized evaluation, 3 times a week dur-
ing one hour each time, during all working shifts (morn-
ing, afternoon, night) and for all health care workers
(physicians, nurses, ancillary staff).
Culture Techniques
VAP
In most cases, a deep tracheal aspirate from the endotra-
cheal tube was cultured aerobically and gram-stained.
CVC-BSI
CVC were removed aseptically and the distal 5 cm of CVC
was amputated and cultured using a standardized semi-
quantitative method [15]. Concomitant blood cultures
were drawn percutaneously in nearly all cases.
CAUTI
A urine sample was aseptically aspirated from the sam-
pling port of UC and cultured quantitatively. In all cases,
standard laboratory methods were used to identify micro-




Ventilator-associated pneumonia is indicated in a
mechanically ventilated patient with a chest radiograph
that shows new or progressive infiltrates, consolidation,
cavitation, or pleural effusion. The patient must also have
at least 1 of the following criteria: new onset of purulent
sputum or change in character of sputum; organism cul-
tured from blood; or isolation of an etiologic agent from
a specimen obtained by tracheal aspirate, bronchial
brushing or bronchoalveolar lavage, or biopsy.
Laboratory-Confirmed CVC-Associated Bloodstream Infection
Central venous catheter-associated bloodstream infection
is laboratory-confirmed when a patient with a CVC has a
recognized pathogen that is isolated from 1 or more per-
cutaneous blood cultures after 48 hours of vascular cathe-
terization and is not related to an infection at another site.
The patient also has at least 1 of the following signs or
symptoms: fever (temperature > 38°C), chills, or hypo-
tension. With skin commensals (for example, diph-
theroids, Bacillus spp., Propionibacterium spp., Coagulase-
negative staphylococci, or micrococci), the organism is cul-
tured from 2 or more blood cultures.
Catheter-Associated Urinary Tract Infection
For the diagnosis of catheter-associated urinary tract infec-
tion, the patient must meet 1 of 2 criteria. The first crite-
rion is when a patient with a urinary catheter has 1 or
more of the following symptoms with no other recog-
nized cause: fever (temperature > 38°C), urgency, or
suprapubic tenderness when the urine culture is positive
for 105 colony-forming units per mL or more, with no
more than 2 microorganisms isolated. The second crite-
rion is when a patient with a urinary catheter has at least
2 of the following criteria with no other recognized cause:
positive dipstick analysis for leukocyte esterase or nitrate,
pyuria (≥ 10 leukocytes per mL of urine), organisms seen
on gram stain, physician diagnosis of urinary tract infec-
tion, or physician initiates appropriate therapy for a uri-
nary tract infection.
Statistical analysis
EpiInfo® version 6.04b (CDC, Atlanta, Ga) was used for
data analysis. Device-utilization rates were calculated by
dividing the total number of device-days by the total
number of patient-days. Rates of VAP, CVC-BSI, and
CAUTI per 1000 device-days were calculated by dividing
the total number of HAI by the total number of specific
device-days and multiplying the result by 1000 [14].
Results
Features of Population Studied
During the three years and 6 months of study in one
Moroccan ICU surveillance data were prospectively col-
lected on 1,731 patients hospitalized in the ICU for
11,297 ICU-days (Table 1). They acquired 251 HAIs, an
overall rate of 14.5% or 22.2 HAIs per 1,000 ICU-days.
VAP represented 54.6% of all HAIs. CAUTI represented
31.9%. CVC-BSI represented 13.5% (Table 2). Individual
characteristics of each ICU, the number of patients
enrolled in the study, the number of ICU-days, APACHE
II score and ASIS are shown in Table 1. Mean patient ASIS,
being 3.88 overall, and APACHE II 11.5.
Device-Utilization Ratio
The ICU device utilization was as follows: for MV, 0.28;
for CVC, 0.19; and for UC, 0.60. Distributions by type of
HAI and device-utilization are shown in Table 2.International Archives of Medicine 2009, 2:29 http://www.intarchmed.com/content/2/1/29
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VAP
The overall rate of VAP in the ICU was 43.16 per 1,000 MV
days (Table 2). Crude mortality of patients with VAP was
81.6%, with extra mortality of 56.7%, (RR 3.28, 95% CI
2.51-4.29, P < 0.001). Patients without HAI presented a
crude mortality rate of 24.9%, yielding an excess mortality
of 56.7%. LOS of patients without HAI was 5.1 days and
of patients with VAP, 10.6 days (RR, 2.08; 95% CI, 1.94 -
2.24; P < 0.0001), representing 5.5 extra days.
CVC-BSI
The overall rate of CVC-BSI in the ICU was 15.71 per
1,000 CVC days (Table 2). The crude mortality of patients
with CVC-BSI was 100%, with extra mortality of 75.1%
(RR 4.02, 95% CI 1.50 - 10.77, P = 0.0027). LOS of
patients with CVC-BSI was 9.0 days (RR, 1.76; 95% CI,
1.27 - 2.45; P = 0.0005), representing 3.9 extra days.
CAUTI
The overall rate of CAUTI in the ICU was 11.7 per 1,000
urinary catheter days (Table 2). Crude mortality of
patients with CAUTI was 43.6%, with extra mortality for
CAUTI of 18.7% (RR 1.75, 95% CI 1.08-2.85, P = 0.0218).
LOS of patients with CAUTI was 13.7 days (RR, 269; 95%
CI, 2.47 - 2.94; P < 0.0001), representing 8.6 extra days.
Use of Antibiotics, Overall Bacterial Profile and Resistance
The use of antibiotics per 1000 ICU days is shown in Table
3. Overall 24.1% of all HAI were caused by Acinetobacter
sp. --78.6% of which were resistant to piperaciline tazo-
bactam; 23.1% was caused by Pseudomonas sp infections -
-35.6% were resistant to ceftazidime and 13.5% to imi-
penem; 15.4% were caused by Klebsiella sp. --75.0% of
which were resistant to ceftriaxone, 69.5% to ceftazidime;
12.8% were caused by E. Coli --31.9% of which were
resistant to ceftriaxone, 21.7% to ceftazidime; 8.2% were
caused by Candida sp; 4.1% by Enterobacter sp --68.4% of
which were resistant to ceftriaxone, 55.6% to ceftazidime,
and 10% to imipenem; 4.6% were caused by S aureus
infections --25.5% of which were resistant to methicilin;
3.1% by Coagulase-negative-staphylococci --78.3% of which
were resistant to methicilin; 2.6% by Proteus sp; 1.0% were
caused by Streptocococcus sp; 1.0% by Serratia sp.
Hand washing compliance
We observed 5,928 patient contacts. The overall HHC rate
was 32.1%. The results stratified by working shifts, type of
contact, and health care workers are shown in Table 4.
Discussion
This study is the first to show HAI rates per 1000 device-
days, bacterial resistance, mortality, and extra LOS in one
Moroccan city. HAI, which can be reduced by 30% apply-
ing targeted device-associated surveillance of HAIs accord-
ing to studies from the Europe and USA, [3,5] increases
healthcare costs and mortality [17-19]. Surveillance forms
were devised by the INICC --founded in 1998 with Latin
American hospitals [8-10,17,20] for data collection of
Table 2: HAIs per 1000 devices days: VAP, CVC-BSI, and CAUTI.
Infection site Device type Device-days Device utilization HAI Distribution of HAI 
(%)
Rate per 100 
patients
Rate per 1000 
device-days
VAP MV 3.174 0.28 137 54.6% 7.9% 43.16
CVC-BSI CVC 2.164 0.19 34 13.5% 2.0% 15.71
CAUTI UC 6,814 0.60 80 31.9% 4.6% 11.74
HAI: Health care associated infection; VAP: Ventilator-associated pneumonia, CVC-BSI: central vascular catheter-associated blood stream infection. 
CAUTI: catheter-associated urinary tract infection; MV: Mechanical Ventilator; UC: Urinary catheter.
Table 3: Use of Antibiotics per 1,000 ICU-days
Antimicrobial class No of defined daily doses Pooled mean
Penicillin group 269 23.81
Ampicillin Group 2290 202.71
Antipseudomonal penicillins 79 6.99
Antistaphylococcal penicillins 3 0.27
First-generation cephalosporins 3 0.27
Second-generation cephalosporins 85 7.52




Vancomycin 197 17.44International Archives of Medicine 2009, 2:29 http://www.intarchmed.com/content/2/1/29
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patients with and without HAI, which enabled the ICP to
match features and determine extra LOS, costs, mortality
[19,20] and major HAI risk factors.
This study showed a lower use of MV (0.28 vs. 0.45), CVC
(0.19 vs. 0.59) and UC (0.60 vs. 0.76) as compared to the
device utilization reported by the US in the National
Healthcare Safety Network (NHSN) [21]. HAI distribu-
tion was: VAP (54.6%), CVC-BSI (13.5%), and CAUTI was
(31.9%), which is similar with the INICC overall data,
where VAP represented 41.0% of all HAIs, followed by
CVC-BSI (30.0%) and CAUTI (29.0%) [7].
Our overall HAI rate per 100 patients, being 14.5%, was
similar than the 14.7% rate of a previous INICC study [7].
The rate of HAI per 1,000 bed-days was 22.2, slightly
lower than the overall INICC rate (22.5/1000) [7].
Our CVC-BSI overall rate was 15.7 per 1000 CVC-days,
which is higher than the INICC overall rate of 12.5, [7]
and much higher than the NHSN 2.9 rate [21]. Our over-
all VAP rate by 1,000 MV-days was 43.2, higher than the
24.1 INICC rate [7] and than the NHSN 3.1 rate [21]. Our
CAUTI rate (11.7 per 1000 UC days) was also higher than
the INICC (8.9) [7] and NHSN (4.4) (table 5) [21].
Extra mortality of patients with VAP was 56.7%, much
higher than the 27.8% found in the INICC study; [7] extra
mortality of patients with CVC-BSI was 75.1%, higher
than the 18.0% of the INICC; and extra mortality of
patients with CA-UTI was 18.7%, which is slightly lower
than the 21.3% found in the INICC study; [7] all them
were significantly higher than the mortality of patients
without HAI.
25.5% of S aureus were MRSA which is lower than the
resistance of 52.9% presented by the NNIS, [4] and much
lower than the 84% rate found in the INICC global study
[7]. We also found a 78.3% Coagulasa negative staphylococci
resistance to methicilin, which is slightly higher than the
NNIS rate (76.6%) [4].
Regarding the resistance of Pseudomonas sp to imipenem,
our 13.5% resistance rate was lower than the NNIS
(19.1%) but our ceftazidime resistance of 35.6% was
higher (35.6% vs 13.9%) [4].
Table 4: Hand Hygiene per Stratum
Hand
Hygiene %
n° of observations Comparisons RR 95%CI P. value
Overall Hand Hygiene 32.1% 5.928 -
Strafied:
Physicians 59.0% 1.684 Ph vs. Nurses 2.63 2.40-2.89 0.0001
Nurses 22.4% 3.824 Nurses vs. Anc Staff 1.74 1.32-2.29 0.0006
Ancillary Staff 12.9% 420 Ph. Vs Anc Staff 4.59 3.49-6.04 0.0001
Men 38.2% 2.370 Men vs Women 1.36 1.24-1.49 0.0001
Women 28.1% 3.558 -
Non invasive contact 26.5% 2.902 Invasive vs non-invasive 1.41 1.29-1.55 0.0001
Invasive contact 37.5% 3.026 -
Morning Shift 38.2% 2.016 Morning vs Afternoon 1.00 0.91-1.11 0.9696
Afternoon Shift 38.1% 2.054 Morning vs Night 2.02 1.78-2.29 0.0001
Night Shift 18.9% 1.858 Night vs Afternoon 2.01 1.77-2.28 0.0001
Table 5: Comparison of device associated infection rates (per 1000 device-days) in the studied Moroccan ICU, in ICUs of the 








U.S. NHSN 2005-2006 Pooled Mean (Interquartile range, 25%-75%)
Medical ICU
CVC-BSI 15.7 12.5 2.9 (0.8-4.2)
CAUTI 11.7 8.9 4.4 (1.8-5.6)
VAP 43.2 24.1 3.1 (0.9-4.6)
CVC-BSI: central vascular catheter-associated blood stream infection, CAUTI: catheter-associated urinary tract infection, VAP: Ventilator-
associated pneumonia.International Archives of Medicine 2009, 2:29 http://www.intarchmed.com/content/2/1/29
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This ICU from Morocco show high HAI rates, the reasons
for this were explained in studies from developing coun-
tries, [12,22] which do not have a legal framework regard-
ing IC programs or their implementation is poor, and
have restricted funds [23,24], low nurse-to-patient staffing
ratios, over-crowded wards, insufficient supplies contrib-
uting to high HAI rates, as stated in studies from US [25].
Also HHC rate is highly variable. In a previous INICC
study, the overall HHC was 51% [26]. In the 2007 study,
the HHC ranged between 49% and 69%.
HAI rates can be reduced by applying HAI surveillance
[3,5], and simple effective IC practices. INICC evidenced
that HHC substantially increased by the institution of pro-
grams, and there was a reduction in the CVC-BSI, CAUTI
and VAP incidence at INICC members [27-33].
Some of our limitations are that our data do not reflect an
entire country, but were collected prospectively over 4
years of comprehensive surveillance in one ICU at a repre-
sentative city of Morocco.
HAI, being a threat to patient safety, requires improve-
ment in clinical practice, by implementing HAI surveil-
lance, and effective infection control interventions.
Conclusion
HAI rates, LOS, mortality, and bacterial resistance were
high in this ICU. Programs including surveillance, infec-
tion control, and antibiotic policy are a priority in
Morocco.
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